- NEWS AND VIEWS
Resistance to prostate-cancer treatment is driven by immune cells
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Nature 559, 338-339 (2018)
doi: https://doi.org/10.1038/d41586-018-05460-y
References
Torre, L. A. et al. CA Cancer J. Clin. 65, 87–108 (2015).
Huggins, C. & Hodges, C. V. J. Urol. 168, 9–12 (2002).
Calcinotto, A. et al. Nature 559, 363–369 (2018).
Pernicová, Z. et al. Neoplasia. 13, 526–536 (2011).
Westin, P., Stattin, P., Damber, J. E. & Bergh, A. Am. J. Pathol. 146, 1368–1375 (1995).
Scher, H. I. et al. J. Clin. Oncol. 26, 1148–1159 (2008).
Ryan, C. J. & Small, E. J. Curr. Oncol. Rep. 7, 228–233 (2005).
Seruga, B., Ocana, A. & Tannock, I. F. Nature Rev. Clin. Oncol. 8, 12–23 (2011).
Grasso, C. S. et al. Nature 487, 239–243 (2012).
Tran, C. et al. Science 324, 787–790 (2009).
Attard, G. et al. J. Clin. Oncol. 26, 4563–4571 (2008).
Veglia, F., Perego, M. & Gabrilovich, D. Nature Immunol. 19, 108–119 (2018).
de Miguel, F., Lee, S. O., Onate, S. A. & Gao, A. C. Nucl. Recept. 1, 3 (2003).
Competing Interests
M.D.G. is the co-founder of RAPPTA therapeutics, which is developing treatments for cancer including castration-resistant prostate cancer.